Sign In
Buy NVAX
$7.89
-0.0600 (-0.755%)
At Close: Aug 10, 2026
NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised
03:41pm, Friday, 07'th Aug 2026
Novavax beat Q2 earnings and revenue estimates, raises its 2026 adjusted revenue outlook, cuts expense guidance and outlines potential Sanofi milestones ahead.
Novavax Q2 Earnings Call Highlights
02:05am, Friday, 07'th Aug 2026
Novavax NASDAQ: NVAX reported second-quarter 2026 revenue of $57 million and a net loss of $53 million, while highlighting progress in its Sanofi partnership, expanding use of its Matrix-M adjuvant pl
Novavax, Inc. (NVAX) Q2 2026 Earnings Call Transcript
06:24pm, Thursday, 06'th Aug 2026
Novavax, Inc. (NVAX) Q2 2026 Earnings Call Transcript
Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimates
10:51am, Thursday, 06'th Aug 2026
Novavax (NVAX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to earnings of $0.62 per share a year ago.
Are Medical Stocks Lagging Novavax (NVAX) This Year?
10:41am, Thursday, 06'th Aug 2026
Here is how Novavax (NVAX) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.
Novavax lifts annual revenue forecast as licensing bets offset weak vaccine demand
08:04am, Thursday, 06'th Aug 2026
Novavax raised its annual revenue forecast after beating quarterly expectations on Thursday, as the vaccine maker's licensing-driven milestone payments helped offset waning demand.
Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights
08:00am, Thursday, 06'th Aug 2026
Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework Improved GAAP Combined R&D and SG&A expense guidance by $10 million at mid-point San
Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026
07:00am, Thursday, 30'th Jul 2026
GAITHERSBURG, Md., July 30, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the Company plans to release its second quarter 2026 financial results before the open of the U.S. fi
Novavax: The Beaten-Down COVID-19 Darling
11:13pm, Tuesday, 28'th Jul 2026
Novavax is significantly undervalued post-COVID, with a current enterprise value around $716 million and a promising pipeline led by Matrix-M. NVAX's Matrix-M adjuvant is a core value driver, validate
Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to Know
06:45pm, Tuesday, 28'th Jul 2026
In the most recent trading session, Novavax (NVAX) closed at $7.37, indicating a -1.6% shift from the previous trading day.
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
10:01am, Wednesday, 22'nd Jul 2026
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Novavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to Note
06:46pm, Monday, 20'th Jul 2026
Novavax (NVAX) reached $7.88 at the closing of the latest trading day, reflecting a -4.02% change compared to its last close.
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why
06:45pm, Tuesday, 14'th Jul 2026
In the latest trading session, Novavax (NVAX) closed at $8.42, marking a -5.5% move from the previous day.
Novavax (NVAX) Suffers a Larger Drop Than the General Market: Key Insights
06:46pm, Wednesday, 08'th Jul 2026
Novavax (NVAX) concluded the recent trading session at $9.35, signifying a -1.16% move from its prior day's close.
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Tuesday, 07'th Jul 2026
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
